{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:35:32Z","timestamp":1780580132194,"version":"3.54.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/rheumatology\/key121","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T12:14:01Z","timestamp":1524053641000},"page":"1423-1431","source":"Crossref","is-referenced-by-count":34,"title":["Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes"],"prefix":"10.1093","volume":"57","author":[{"given":"Mark C","family":"Genovese","sequence":"first","affiliation":[{"name":"Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"van Adelsberg","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunpeng","family":"Fan","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme, Bridgewater, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M H","family":"Graham","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"van Hoogstraten","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme, Bridgewater, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janie","family":"Parrino","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K","family":"Mangan","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Spindler","sequence":"additional","affiliation":[{"name":"Centro Medico Privado de Reumatologia, Tucum\u00e1n, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W J","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"EXTEND study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"key\n\t\t\t\t20180723035931_key121-B1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180723035931_key121-B2","first-page":"vi28","article-title":"Evolution of treatment for rheumatoid arthritis","volume":"51(Suppl 6)","author":"Upchurch","year":"2012","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180723035931_key121-B3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180723035931_key121-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180723035931_key121-B5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X10378372","article-title":"The role of interleukin 6 in the pathophysiology of rheumatoid arthritis","volume":"2","author":"Srirangan","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"key\n\t\t\t\t20180723035931_key121-B6","year":"2016"},{"key":"key\n\t\t\t\t20180723035931_key121-B7","doi-asserted-by":"crossref","first-page":"A797","DOI":"10.1136\/annrheumdis-2013-eular.2360","article-title":"Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6r) alpha","volume":"72(Suppl 3)","author":"Rafique","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180723035931_key121-B8","doi-asserted-by":"crossref","first-page":"A375","DOI":"10.1136\/annrheumdis-2013-eular.1148","article-title":"FRI0020 Preclinical development of sarilumab, the first fully human monoclonal antibody (MAB) against IL-6r alpha: utilization and value of double humanized animal model","volume":"72(Suppl 3)","author":"Wang","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180723035931_key121-B9","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1158\/1538-7445.AM2012-2723","article-title":"Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker aflibercept","volume":"72(8 Suppl)","author":"Zhang","year":"2012","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20180723035931_key121-B10","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180723035931_key121-B11","article-title":"Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with RA","volume":"67(Suppl 10)","author":"Emery","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180723035931_key121-B12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20180723035931_key121-B13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180723035931_key121-B14","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180723035931_key121-B15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40744-016-0043-1","article-title":"Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study","volume":"3","author":"Kivitz","year":"2016","journal-title":"Rheumatol Ther"},{"key":"key\n\t\t\t\t20180723035931_key121-B16","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20180723035931_key121-B17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/ard.2005.044404","article-title":"Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study","volume":"65","author":"Weinblatt","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180723035931_key121-B18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180723035931_key121-B19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/annrheumdis-2017-eular.3513","article-title":"Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis","volume":"76(Suppl 2)","author":"Genovese","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/8\/1423\/25193914\/key121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:14:50Z","timestamp":1751570090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/57\/8\/1423\/4994390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,5,9]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key121","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,5,9]]}}}